RET oncogene-expressing MTC has been reported to retain dependence on RET activity for the maintenance of the malignant phenotype (i.e., oncogene addiction [28]) and, consequently, RET receptor represents an ideal therapeutic target. This evidence concerns the gene RET and medullary thyroid gland carcinoma.